Lindbrook Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Lindbrook Capital’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-383,351	Closed	-$4.61M	–	2874
2022 Q4	$4.61M	Buy	+383,351	New	+$2.98M	0.57%	28

Other funds holding ORMP

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

SIGI

Susquehanna International Group (Ireland) Dublin, Ireland $472M AUM 25.62% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lindbrook Capital's ORMP Position: Q1 2023 in Review

Lindbrook Capital sold out of Oramed Pharmaceuticals (ORMP) in Q1 2023, closing a stake of 383,351 shares — an estimated $4.61M sold.

Lindbrook Capital first reported a position in ORMP in Q4 2022 and held it in 1 quarter. The position peaked at $4.61M in Q4 2022. 61 funds tracked by Wall St. Rank hold ORMP as of Q1 2023.

Lindbrook Capital reported no remaining Oramed Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Lindbrook Capital sold 383,351 Oramed Pharmaceuticals shares in Q1 2023, an estimated $4.61M.
Lindbrook Capital first reported a position in Oramed Pharmaceuticals in Q4 2022 and held it in 1 quarter.
Lindbrook Capital's Oramed Pharmaceuticals position peaked at $4.61M in Q4 2022.
61 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2023.

Based on Lindbrook Capital's 13F filing for Q1 2023, filed 26 Apr 2023.